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Long Term Follow-Up of Patients with Acute
Myelogenous Leukemia Who Received the
Daunorubicin, Vincristine, and Cytosine
Arabinoside Regimen
BACKGROUND. In 1985, the authors published a study of acute myelogenous leuke-Yves Beguin, M.D., Ph.D.
mia (AML) patients treated with a chemotherapeutic regimen that was then consid-Brieuc Sautois, M.D.
ered intensive. Ten years later, the authors reanalyzed the same cohort to deter-Patricia Forget, M.D.
mine whether the very promising actuarial results observed at 5 years held afterJean Bury, M.D.
longer follow-up.Georges Fillet, M.D., Ph.D.
METHODS. Between 1977 and 1982, 61 patients with AML were treated with a
protocol consisting of daunorubicin, vincristine, and cytosine arabinoside induc-Department of Medicine, Division of Hematol-
tion followed by consolidation and maintenance for a total of 2 years. The completeogy, University of Lie`ge, Lie`ge, Belgium.
remission (CR) rate was 66%, 84% in males versus 47% in females (P  0.005). At
the time of the first analysis in 1984, the overall survival (OS) was 17%, the projected
5-year continuous CR rate (CCR) 32%, and the disease free survival (DFS) rate
29%, with the best results observed for males and for patients ages 40–60 years
(P  0.05).
RESULTS. When the data were reanalyzed 11 years later in 1995, the results were
14% OS, 23% CCR, and 16% DFS at 5 years. However, these figures dropped to
8%, 18%, and 11% at 10 years and to 8%, 12%, and 7% at 15 years, respectively.
Among the 40 CR patients, 31 relapsed (up to 13 years after CR), and all died
within 1.6 years after relapse. Nine patients were in CCR: 4 died of unrelated causes
(suicide, alcoholic cirrhosis, acute peritonitis, or bladder carcinoma), 1 was lost to
follow-up after 11 years, 2 were alive and well at 17 years at last follow-up, and 2
were transplanted in first CR and were doing well at 13 and 14 years at last follow-
up. The survival advantage for males over females persisted (P  0.0197), but the
advantage for patients age 40–60 years did not hold.
CONCLUSIONS. These long term data indicate that actuarial analysis at 5 years may
overestimate the cure rate of AML patients because a number of late relapses do
occur. However, the picture is blurred by the incidence of death not related to
leukemia or its treatment; and when these patients were censored at the time of
death, 17% of CR patients were still projected to be alive and free of leukemia after
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patients with acute myelogenous leukemia (AML) were published in
Cancer.1 The complete remission (CR) rate was 66 %, median survivalReceived August 12, 1996; revision received
was 21 months, and median remission duration was 13 months withNovember 26, 1996; accepted November 26,
1996. a projected CR rate of 30 % at 5 years. These results were considered
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very encouraging at that time. In the current study,
we reanalyzed the same cohort of patients after more
than 11 years of additional follow-up to examine
whether the promising results observed at 6.5 years of
follow-up would hold after a much longer period of
observation.
PATIENTS AND METHODS
As previously published,1 61 patients (30 females and
31 males) were treated with the DOA protocol between
1977 and 1982. Age ranged from 12 to 76 years (me-
dian, 51 years), with only one patient over 70. Induc-
tion therapy consisted of daunorubicin (DNR) 60 mg/
m2 given intravenously (i.v.) on Days 1, 2 and 6; vin-
cristine (VCR) 1 mg/m2 i.v. on Day 2; and cytosine FIGURE 1. Duration of complete remission (CR) is shown. The analysis
arabinoside (Ara-C) 3 1 80 mg/m2 i.v. on Days 3– of the 1984 data (continuous line) is compared with the analysis of the
7. After 2 consolidation courses, patients underwent 1995 data (broken line) for the same cohort of 40 CR patients (differences
monthly maintenance and intensification courses for not significant).
up to 2 years after diagnosis, as described previously.1
Informed consent was obtained from the patients or
their guardians. Data as of August 1, 1995, was ana- All relapsed patients died within 1.6 years at a median
of 0.4 years: 6 were not reinduced, 8 died during rein-lyzed and compared with the analysis performed pre-
viously on data obtained as of January 1, 1984. Actuar- duction, 4 died of resistant disease, 4 died of complica-
tions while in second CR, 6 died while in second re-ial remission and survival analyses were performed
using the Kaplan-Meier product limit method. Com- lapse, and 3 died after BMT.
parison between survival curves were made using the
log rank test. All survival analyses were carried out Continuous Complete Remission
At last follow-up, nine patients (23 %) had been inwith Graphpad Prism software (Graphpad Software,
San Diego, CA). Two patients undergoing bone mar- continuous CR: 2 were alive and well more than 17
years after CR, 1 was lost to follow-up after more thanrow transplantation (BMT) while in their first complete
remission (CR) were censored for CR duration and 11 years, and the 2 patients who underwent BMT while
in first CR were well 13 and 14 years later. However,survival at the time of transplantation.
four patients died while in CR of unrelated causes, i.e.,
suicide, alcoholic cirrhosis, postoperative peritonitis,RESULTS
Complete Remission and bladder carcinoma.
The results of induction therapy were published pre-
viously.1 Briefly, among 61 patients, 40 (66%) achieved Duration of Response
Data analyzed as of January 1, 1984, gave a median CRCR after 1 (n  30) or 2 (n  10) courses of induction,
whereas 9 (15%) died during aplasia and 12 (20%) ex- duration of 1.1 years, with 32% of patients projected to
be still in CR at 5 years. When the data as of Augustperienced induction failure. CR was achieved among
84% of males versus 47% of females (P  0.005) and 1, 1995, were analyzed, the median CR duration did
not change, but the CR rate dropped to 23% at 5 years,among 82% of patients younger than 40 years versus
59% of older patients (not significant). No other prog- 18% at 10 years, and 12% at 15 years (Fig. 1). Although
the 1984 analysis identified age 40–60 years as a favor-nostic factors were identified for response.
able prognostic factor for CR duration (52% at 5 years
vs. 10% for younger or older patients, P  0.0335), theRelapses
Among the 40 CR patients, 31 (78%) relapsed. Seven difference disappeared completely in the 1995 analy-
sis. However, the significant advantage of male gender(18%) relapsed within 6 months of CR, 11 (28%) be-
tween 6 months and 1 year, 9 (23%) between 1 and 2 (median CR duration, 1.7 vs. 1.0 years, and CR rate at
5 years, 35% vs. 0%, P  0.0197) confirmed previousyears, and 4 (10%) at 2.5, 3, 6, and 13 years, respec-
tively. Of the 31 relapses, 25 were reinduced and 13 findings. No other prognostic factor was identified.
Although a plateau of continuous remission was ap-(52%) achieved a second CR. Two of them underwent
allogeneic BMT while in second relapse, and one of parent in the 1984 analysis, the occurrence of late re-
lapses sent the curve several steps downward.them underwent allogeneic BMT while in second CR.
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same as the one reported for studies performed ear-
lier4 and later.5–7 Only one other recent study, in which
high dose Ara-C was used for consolidation, reported
a better outcome of about 25% survival at 10 years,
but only patients younger than 50 years with de novo
AML were selected.8
In our study, 18% of CR patients relapsed within
6 months, 28% between 6 months and 1 year, 23%
between 1 and 2 years, and 10% after 2 years. The
relapse rate was still 40% among patients who did not
undergo BMT and were still in CR after 2 years, and
29% among those still in CR at 5 years. Because of
relapses occurring up to 13 years after CR, the CR rate
dropped from 32% at 5 years in the 1984 analysis to
23% at 5 years and only 12% at 15 years in the currentFIGURE 2. Overall survival of patients in complete remission is shown.
analysis. As discussed by Preisler et al,9 early relapsesPatients who died of causes unrelated to leukemia or its treatment were
may represent the regrowth of leukemic cells presentcensored at the time of death.
at diagnosis and late relapses caused by the over-
growth of rare drug-resistant or quiescent cells. The
current study indicates that because relapses indeed
Survival occur very late, a true plateau may never exist in acute
Overall survival among the 61 patients was 59% at 1 nonlymphocytic leukemia (ANLL). As the existence of
year, 30% at 2 years, 15% at 5 years, 10% at 10 years, a plateau is often used as an indication of cure, this
and 7% at 15 years, with a median of 1.3 years. Survival observation may give the depressing message that cure
of CR patients was better, with 88 %, 43%, 23%, 15% may not be certain even after very long follow-up.
and 11% survival at 1, 2, 5, 10, and 15 years, respec- More specific treatment, i.e., with monoclonal anti-
tively, and a median of 1.7 years. Censoring for BMT bodies or differentiating agents, may thus be needed
in first CR further decreased survival of CR patients to in addition to chemotherapy.
19% at 5 years, 11% at 10 years, and 7% at 15 years. Another factor contributing to poor survival is
This produced disease free survival rates of 16%, 11%, death from causes thought to be unrelated to leukemia
and 7% at 5, 10, and 15 years, respectively, with a or its treatment, i.e., postoperative peritonitis, bladder
median of 1.1 years. When patients dead from unre- carcinoma, alcoholic cirrhosis, and suicide, all oc-
lated causes were censored at the time of death, overall curring within 6 years of CR. However, these deaths
survival of CR patients increased to 26% at 5 years, may not be totally unrelated to leukemia, as prolonged
23% at 10 years, and 17% at 15 years (Fig. 2). However, relative immunosuppression may cause a higher sus-
censoring for BMT in first CR made these values drop ceptibility to infections, chemotherapy may induce
by 5%. Male gender bore a favorable prognosis as com- secondary cancers, and the strenuous experience of
pared with female gender for survival of all patients leukemia and its treatment may produce or aggravate
(P  0.0005), disease free survival (P  0.0239) and behavioral or psychologic disorders. Nonetheless, the
overall survival of CR patients (P  0.0287). Other fac- rate of death from unrelated causes may have been
tors, including age, did not show prognostic signifi- particularly high in our study and has not been repro-
cance for survival. duced in larger trials.
Another effect of longer follow-up on the results
is the disappearance of any advantage for patients ageDISCUSSION
In the current study, we updated results initially pub- 40–60 years as compared with younger or older pa-
tients. On the other hand, contrary to most other stud-lished in 1985,1 with only 1 patient lost to follow-up
after 11 years. Follow-up ranged from 11 to 17 years, ies, female gender remained a significant adverse
prognostic factor for CR rate and duration. This wasthe longest published for any AML trial (a few other
studies have had follow-up extending to a maximum not explained by the association of female gender with
other classical adverse prognostic factors. We mustof 12.5 years). The CR rate of 18% at 10 years and the
overall survival of 10% at 10 years are quite similar to acknowledge that this particular finding is probably
due to small numbers. However, we cannot rule outlong term results from large multicenter studies per-
formed during the same period.2,3 The range of 8–15% the possibility that female gender truly is an adverse
prognostic factor when patients are treated with theoverall survival at 7–10 years in these studies is the
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chemotherapy with a minimal follow-up of 7 years. Br JDOA regimen but is no longer an adverse factor when
Haematol 1991;77:486–90.patients receive more effective induction and consoli-
6. Ghaddar HM, Plunkett W, Kantarjian HM, Pierce S, Freireich
dation therapy, as in our more recent trials (data not EJ, Keating MJ, et al. Long-term results following treatment
shown). of newly-diagnosed acute myelogenous leukemia with con-
tinuous-infusion high-dose cytosine arabinoside. LeukemiaThe overall survival rate of 7% at 15 years obtained
1994;8:1269–74.in this study, which was initiated in the late 1970s
7. Volger WR, Weiner RS, Moore JO, Omura GA, Bartolucciand early 1980s, of course does not take into account
AA, Stagg M. Long-term follow-up of a randomized post-
significant advances in the treatment of ANLL that induction therapy trial in acute myelogenous leukemia: a
have occurred since that time.10 The application of Southeastern Cancer Study Group trial. Leukemia 1995;
9:1456–60.idarubicin for induction11 and the use of intermediate/
8. Heil G, Mitrou PS, Hoelzer D, Freund M, Link H, Ehningerhigh dose cytosine arabinoside for induction,12 consol-
G, et al. High-dose cytosine arabinoside and daunorubicinidation,13 or both14 are very encouraging but await
postremission therapy in adults with de novo acute myeloid
confirmation after longer follow-up. The increasing leukemia: long-term follow-up of a prospective multicenter
use of autologous or allogeneic BMT will certainly have trial. Ann Hematol 1995;71:219–25.
9. Preisler HD, Anderson K, Rai K, Cuttner J, Yates J, Du Prea profound effect on the outcome of ANLL patients.15
E, et al. The frequency of long-term remission in patientsHowever, our study indicates that the final impact of
with acute myelogenous leukaemia treated with conven-
newer approaches in the treatment of ANLL must al- tional maintenance chemotherapy: a study of 760 patients
ways be evaluated after very long periods of observa- with a minimal follow-up time of 6 years. Br J Haematol
1989;71:189–94.tion.
10. Rowe JM, Liesveld JL. Treatment and prognostic factors in
acute myeloid leukemia. Clin Haematol 1996;9:87–105.
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